These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

523 related articles for article (PubMed ID: 16890611)

  • 1. The essential role of insulin-like growth factor-1 in the intestinal tropic effects of glucagon-like peptide-2 in mice.
    Dubé PE; Forse CL; Bahrami J; Brubaker PL
    Gastroenterology; 2006 Aug; 131(2):589-605. PubMed ID: 16890611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of phosphatidylinositol-3 kinase-gamma in the actions of glucagon-like peptide-2 on the murine small intestine.
    Anini Y; Izzo A; Oudit GY; Backx PH; Brubaker PL
    Am J Physiol Endocrinol Metab; 2007 Jun; 292(6):E1599-606. PubMed ID: 17284578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of glucagon-like peptide-2-induced proliferation following intestinal epithelial insulin-like growth factor-1-receptor deletion.
    Rowland KJ; Trivedi S; Lee D; Wan K; Kulkarni RN; Holzenberger M; Brubaker PL
    Gastroenterology; 2011 Dec; 141(6):2166-2175.e7. PubMed ID: 21925122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin-like growth factor (IGF) 2 stimulates steroidogenesis and mitosis of bovine granulosa cells through the IGF1 receptor: role of follicle-stimulating hormone and IGF2 receptor.
    Spicer LJ; Aad PY
    Biol Reprod; 2007 Jul; 77(1):18-27. PubMed ID: 17360960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of glial cell-line derived neurotropic factor family receptor alpha2 in the actions of the glucagon-like peptides on the murine intestine.
    McDonagh SC; Lee J; Izzo A; Brubaker PL
    Am J Physiol Gastrointest Liver Physiol; 2007 Aug; 293(2):G461-8. PubMed ID: 17585017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucagon like peptide-2 induces intestinal restitution through VEGF release from subepithelial myofibroblasts.
    Bulut K; Pennartz C; Felderbauer P; Meier JJ; Banasch M; Bulut D; Schmitz F; Schmidt WE; Hoffmann P
    Eur J Pharmacol; 2008 Jan; 578(2-3):279-85. PubMed ID: 17920582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ErbB signaling is required for the proliferative actions of GLP-2 in the murine gut.
    Yusta B; Holland D; Koehler JA; Maziarz M; Estall JL; Higgins R; Drucker DJ
    Gastroenterology; 2009 Sep; 137(3):986-96. PubMed ID: 19523469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucagon-like peptide-2 receptor modulates islet adaptation to metabolic stress in the ob/ob mouse.
    Bahrami J; Longuet C; Baggio LL; Li K; Drucker DJ
    Gastroenterology; 2010 Sep; 139(3):857-68. PubMed ID: 20546737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Naturally occurring glucagon-like peptide-2 (GLP-2) receptors in human intestinal cell lines.
    Sams A; Hastrup S; Andersen M; Thim L
    Eur J Pharmacol; 2006 Feb; 532(1-2):18-23. PubMed ID: 16448646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ErbB activity links the glucagon-like peptide-2 receptor to refeeding-induced adaptation in the murine small bowel.
    Bahrami J; Yusta B; Drucker DJ
    Gastroenterology; 2010 Jun; 138(7):2447-56. PubMed ID: 20226187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-10-independent anti-inflammatory actions of glucagon-like peptide 2.
    Ivory CP; Wallace LE; McCafferty DM; Sigalet DL
    Am J Physiol Gastrointest Liver Physiol; 2008 Dec; 295(6):G1202-10. PubMed ID: 18845573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucagon-like peptide 2 improves intestinal wound healing through induction of epithelial cell migration in vitro-evidence for a TGF--beta-mediated effect.
    Bulut K; Meier JJ; Ansorge N; Felderbauer P; Schmitz F; Hoffmann P; Schmidt WE; Gallwitz B
    Regul Pept; 2004 Sep; 121(1-3):137-43. PubMed ID: 15256284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucagon-like peptide-2 and common therapeutics in a murine model of ulcerative colitis.
    L'Heureux MC; Brubaker PL
    J Pharmacol Exp Ther; 2003 Jul; 306(1):347-54. PubMed ID: 12815012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ontogeny of the glucagon-like peptide-2 receptor axis in the developing rat intestine.
    Lovshin J; Yusta B; Iliopoulos I; Migirdicyan A; Dableh L; Brubaker PL; Drucker DJ
    Endocrinology; 2000 Nov; 141(11):4194-201. PubMed ID: 11089553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The "cryptic" mechanism of action of glucagon-like peptide-2.
    Rowland KJ; Brubaker PL
    Am J Physiol Gastrointest Liver Physiol; 2011 Jul; 301(1):G1-8. PubMed ID: 21527727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Involvement of insulin-like growth factor-I for the regulation of prolactin synthesis by estrogen and postnatal proliferation of lactotrophs in the mouse anterior pituitary.
    Saitoh Y; Hikake T; Hayashi S; Iguchi T; Sato T
    Cell Tissue Res; 2010 Apr; 340(1):147-58. PubMed ID: 20198387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucagon-like peptide 2 (GLP-2) accelerates the growth of colonic neoplasms in mice.
    Thulesen J; Hartmann B; Hare KJ; Kissow H; Ørskov C; Holst JJ; Poulsen SS
    Gut; 2004 Aug; 53(8):1145-50. PubMed ID: 15247183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intestinotrophic glucagon-like peptide-2 (GLP-2) activates intestinal gene expression and growth factor-dependent pathways independent of the vasoactive intestinal peptide gene in mice.
    Yusta B; Holland D; Waschek JA; Drucker DJ
    Endocrinology; 2012 Jun; 153(6):2623-32. PubMed ID: 22535770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of constitutive IGF1/IGF2 stimulation on the transcriptional program of human breast cancer cells.
    Pacher M; Seewald MJ; Mikula M; Oehler S; Mogg M; Vinatzer U; Eger A; Schweifer N; Varecka R; Sommergruber W; Mikulits W; Schreiber M
    Carcinogenesis; 2007 Jan; 28(1):49-59. PubMed ID: 16774935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Calvariae from fetal mice with a disrupted Igf1 gene have reduced rates of collagen synthesis but maintain responsiveness to glucocorticoids.
    Woitge HW; Kream BE
    J Bone Miner Res; 2000 Oct; 15(10):1956-64. PubMed ID: 11028448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.